Article
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Urologia Internationalis (impact factor:
0.99).
02/2002;
68(1):16-23.
pp.16-23
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
androgen ablation
androgen receptor
CAG length
CAG repeat lengths
Gleason score
higher histological grade
histologically
hormonal therapy
individual's susceptibility
inverse relationship
major role
PCR
polymorphic CAG repeat
polymorphic trinucleotide repeat
prostate cancer
prostatic growth
Serum samples
shorter CAG lengths
significant correlation
survival time